CClinicalTrials.gg
RecruitingNCT05378243Updated Aug 29, 2023

Innovative Robotic Gait Trainer Use to Enable Walking in Children With Cerebral Palsy GMFCS III and IV

An interventional study of Robotic Gait Training and Functional Clinical Therapy in Cerebral Palsy, sponsored by Children's Hospital of Eastern Ontario. Recruiting at 1 site in Canada. Open to participants aged 2 Years to 12 Years. Per ClinicalTrials.gov, last updated 2023-08-29.

Sponsored by Children's Hospital of Eastern Ontario · Not applicable, Interventional, and Device feasibility

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 6 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Nov 2021, registered May 2022).
  • Started Nov 2021; still recruiting 4 years 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
2 Years to 12 Years
Sex
All
01

Study summary

Exploration to optimize mixed quantitative and qualitative methodology using multiple outcome measures in a randomized, cross-over trial structure comparing the effect of robotic gait training (RGT) group, and functional clinical therapy (FCT) using each subject as their own control.

Read the detailed description

Exploration to optimize mixed quantitative and qualitative methodology using multiple outcome measures in a randomized, cross-over trial structure comparing the effect of robotic gait training (RGT) group, and functional clinical therapy (FCT) using each subject as their own control.

The primary objective is to assess feasibility of the study design and device tolerability. Specifically:

  • Recruitment success (number screened, number eligible, number enrolled) where 80% of the recruitment target is reached.
  • Attrition rates of less than 10% (i.e. ≥90% of participant's successfully complete assessments).
  • Adherence for each participant: 80% of participants who complete assessments achieve the minimum target dose (i.e. approx. ≥30 hours of therapy in both study groups).
  • Qualitative feedback from clinicians and patients/caregivers on device tolerability and study participation.

Secondary objectives will evaluate the distance a child can walk in two minutes using the Two Minute Walk Test (2MWT, 18) and will examine a more global impact of the use of this technology. Data collected will include quality of gait, child or proxy chosen individualized goals, hypertonicity, contractures, and bone health.

02

Conditions studied

  • Cerebral Palsy

Browse trials for

03

In context

Cerebral Palsy

1,853 studies on the registry are indexed under Cerebral Palsy; 435 are open to participants now.

This study's planned enrollment of 10 is below the median of 33 across 1,368 interventional studies indexed under Cerebral Palsy.

Browse Cerebral Palsy studies →

Lead sponsor

Children's Hospital of Eastern Ontario is the lead sponsor of 83 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with a diagnosis of cerebral palsy
  • GMFCS Levels III and IV
  • Ages ≥2 to ≤12 years
  • Ability to take steps with and/or without assistance
  • Meet the Trexo Plus device size requirements
  • Ability to follow instructions and signal pain, fear, or discomfort
  • Ability to safely use the device at home as determined by the study team

Exclusion criteria

Exclusion Criteria:

  • Lower limb or orthopedic surgery within 9 months prior to enrollment
  • Botulinum toxin injections within 4 months prior to enrollment
  • Serial casting within 3 months prior to enrollment
  • Knee flexion contracture > 20°
  • Knee valgus > 40°
  • Hip subluxation > 40 % migration percentage
  • Uncontrolled movements that prevent transfer in and/or out of device
  • Weight bearing restrictions
  • Uncontrolled seizures
  • Skin lesions in areas where the device straps would be attached
  • Significant language barrier with parents and/or caregivers Note: children with severe contractures will be unable to fit in the device and are therefore excluded from the study
05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Robotic Gait Training

    8 weeks of therapy with the robotic gait training device 4-5 times a week for 1 hour each session

    Device: Robotic Gait Training

  • Experimental
    Functional Clinical Therapy

    8 weeks of therapy with a custom designed therapy program for the participant's needs 4-5 times a week for 1 hour each session

    Behavioral: Functional Clinical Therapy

Interventions

  • DeviceRobotic Gait Training

    Use of a walker adapted with robotic components to promote proper walking gait

  • BehavioralFunctional Clinical Therapy

    Personalized program of physical therapy targeted to improving walking gait

06

What researchers measure

Primary outcomes

  1. Enrollment and recruitment in this study design

    Recruitment success as defined by meeting 80% of the recruitment target

    Time frame: 4 months

  2. Retention in this study design

    Attrition of less than 10% where 90% of participants are completing the assessments to the end of the trial

    Time frame: 4 months

  3. Adherance to protocol for each participant

    Participant self-reported session diaries will be assessed to determine whether participants are achieving the min target dose of 30h of therapy over each 8 week session

    Time frame: 4 months

  4. Device tolerability

    Participant caregivers will be interviewed for qualitative feedback on device/therapy tolerability after each 8 week session

    Time frame: 4 months

Secondary outcomes

  1. 2 minute walk test (2mwt)

    distance child is able to walk in their own walker in 2 minutes

    Time frame: 4 months

  2. Edinburgh Visual Gait Score

    Edinburgh Visual Gait Score is used for assessing gait quality by assessing body positions and angles of various body parts through the gait pattern using a scale of 0-2 for each individual component of the assessment. A score of 0 indicates a more physiologically normal result while a score of 2 indicates a more disordered result. The scores are totaled to provide the complete score for the patient on this assessment

    Time frame: 4 months

  3. Physiological Cost Index

    assessing gait efficiency by looking at the heart rate changes upon a specified exertional task. A lower physiological cost index indicates less exertion required to complete the task

    Time frame: 4 months

  4. Modified Ashworth Scale

    The Modified Ashworth Scale measures resistance during passive soft tissue stretching. It is ranked by body part on a scale of 0-4 with 0 being a normal tone and 4 being highly rigid in flexion or extension.

    Time frame: 4 months

  5. Hypertonia Assessment Tool

    Assessing dystonia, spasticity, and rigidity, or a mixed tone through a rating scale system where 0 indicates the behavior is not observed and 1 indicates the dystonic/spastic/rigid behavior is observed.

    Time frame: 4 months

  6. Barry Albright Dystonia Scale

    Assessing dystonia and severity of dystonia in eyes, mouth, neck, trunk, each upper extremity and each lower extremity. Scored from 0-4 where 0 is an absence of dystonia and 4 is a high degree of dystonia.

    Time frame: 4 months

  7. Goal attainment scale

    Attainment of self-determined goals for treatment outcomes. Goals are set with the study therapists at the outset of each treatment period and assessed using a scale of -2 to +2 where a score of 0 is the expected outcome, a negative score indicates less than expected and a positive number indicates more than expected

    Time frame: 4 months

  8. Spinal Alignment and Range of Motion Measure

    Range of motion throughout the body is measured from 0-4 where 0 is no limitation and 4 is a severe limitation.

    Time frame: 4 months

  9. Leg Bone cortical density

    peripheral Quantitative Computed Tomography (pQCT) Measures Cortical density (mg/cm2)

    Time frame: 4 months

  10. Tibia volumetric bone mineral density (BMD)

    peripheral Quantitative Computed Tomography (pQCT) Measures Tibia volumetric bone mineral density (BMD) (mg/cm2)

    Time frame: 4 months

  11. Leg bone cortical cross-sectional area

    peripheral Quantitative Computed Tomography (pQCT) Measures cortical cross-sectional area (mm2)

    Time frame: 4 months

07

Study locations

1 of 1 sites recruiting
  • Children's Hospital of Eastern Ontario
    Ottawa, Ontario, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — There is no intention to share IPD with other researchers

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05378243
Lead sponsor
Children's Hospital of Eastern Ontario
Collaborators
Ontario Brain Institute, Academic Health Science Centres
Responsible party
Anna McCormick (Pediatrician / Physical Medicine and Rehabilitation Specialist, Division Chief Developmental Medicine and Rehabilitation, Children's Hospital of Eastern Ontario) — Principal investigator
First posted
May 18, 2022
Start date
Nov 8, 2021
Primary completion
Mar 31, 2024 (estimated)
Completion
Jul 31, 2024 (estimated)
Last update
Aug 29, 2023

Study contacts

Michelle Larin
Contact
MLarin@cheo.on.ca
6137377600 ext. 4359

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion